Bli medlem
Bli medlem

Du är här

2016-12-08

Oxford Immunotec Announces New England Journal of Medicine Publication on Clinical Trial Results of Serological and Nucleic Acid Tests for Babesia in Blood Scre

Oxford Immunotec
Release

Oxford Immunotec Announces New England Journal of Medicine Publication on
Clinical Trial Results of Serological and Nucleic Acid Tests for Babesia in
Blood Screening

OXFORD, United Kingdom and MARLBOROUGH, Mass., 2016-12-08 13:00 CET (GLOBE
NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth
diagnostics company focused on developing and commercializing proprietary tests
for the management of underserved immune-regulated conditions, today announced
that the New England Journal of Medicine (“NEJM”) has published an article on a
three-year clinical trial completed by Oxford Immunotec’s Imugen division, and
the American Red Cross (“ARC”) to evaluate a serology and Nucleic acid
Amplification Test (“NAT”) testing regime for Babesia in blood screening. The
review article “Screening for Babesia microti in the US blood supply” is
authored by Susan Stramer of the American Red Cross, and will appear in the
December 8, 2016 print issue.

Babesia, or babesia microti, is a parasitic protozoan transmitted by ticks and
is particularly prevalent in the Northeastern part of the US. It infects red
blood cells and can cause a disease called Babesiosis. In addition to becoming
infected via a tick bite, patients can get Babesia through blood transfusions
from Babesia-infected donors. Babesia is a significant and growing cause of
transfusion-associated infections; however, no Babesia test is yet approved by
the FDA for blood screening. Imugen has developed both a serology test and a
NAT for Babesia for use in blood screening.

The clinical trial, completed under an FDA Investigational New Drug (“IND”)
application, screened approximately 90,000 blood samples to evaluate the
effectiveness of Imugen’s serology and NAT testing regime in detecting
Babesia-infected donors. No reported cases of transfusion-transmitted
Babesiosis were associated with the 75,331 screened donations from high risk
states as compared to 14 cases per 253,031 unscreened donations. The clinical
trial determined that Imugen’s testing regime is effective in detecting Babesia
in blood samples.

“The data in the publication in the New England Journal of Medicine provide
compelling evidence on the efficacy of the Babesia screening regime that Imugen
has developed in conjunction with the ARC,” said Peter Wrighton-Smith, Ph.D.,
Chief Executive Officer of Oxford Immunotec. “We look forward to progressing
these Babesia assays through the FDA approval process and ultimately to
commercialization for blood screening.”

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company
focused on developing and commercializing proprietary tests for the management
of underserved immune-regulated conditions. The Company’s first product is the
T-SPOT®.TB test, which is used to test for tuberculosis infection. The
T-SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The company’s second product line is a range of assays for tick-borne
diseases, such as Lyme disease, obtained through the acquisitions of Imugen and
Immunetics. The T-SPOT.CMV test and the T-SPOT.PRT test are part of the
Company’s third product line focused on the transplantation market. In addition
to these three product lines, the Company has additional active development
programs in other immune-regulated conditions. The Company is headquartered
near Oxford, U.K. and in Marlborough, Mass. Additional information can be found
at www.oxfordimmunotec.com.

T-SPOT, the Imugen logo and the Oxford Immunotec logo are trademarks of Oxford
Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.

CONTACTS:

For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
ccrawley@oxfordimmunotec.com

For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
raltieri@oxfordimmunotec.com

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501
oxfordimmunotec@westwicke.com

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.